• To become a world-leading AI drug design company and redefine the development of peptide and protein drugs.
• De novo protein design has become the mainstream approach for new drug discovery, reducing the preclinical research and development cycle from years to months.
•Breaking through the boundaries of "undruggable" targets, dynamic conformation prediction technology activates the space of random protein targets that account for more than 30% of the human proteome.
• Continuously iterate on core algorithms to maintain a technological advantage in the field of de novo protein design.
• We provide comprehensive one-stop design and screening solutions for pharmaceutical, diagnostic, and synthetic biology companies.
• Accelerate the entry of multiple proprietary pipelines into preclinical and clinical stages, and validate the platform's output efficiency and drugability.
•Achieve a dual-engine growth model of "platform services + pipeline assets" to create a sustainable positive cycle of cash flow and R&D investment.
Our company is dedicated to accelerating protein drug design research, focusing on developing a self-managed peptide pipeline. The global peptide drug market has maintained steady growth. Between 2010 and 2018, the market size grew from US$15.2 billion to US$28.5 billion, with a compound annual growth rate of 8.17%. In 2018, the global pharmaceutical market size was approximately US$1.3 trillion, with peptide drugs accounting for 2.19%, indicating a still relatively low penetration rate. During the same period, the peptide drug market grew at approximately twice the rate of the overall global pharmaceutical market, demonstrating strong growth momentum.
Industry forecasts predict that the global peptide drug market will continue to expand at a CAGR of 7.9%, reaching $35.8 billion in 2021 and expected to approach $49.5 billion in 2027. The Chinese peptide drug market is also experiencing rapid growth, increasing from $6.3 billion in 2016 to $8.5 billion in 2020, representing a CAGR of 8%. In recent years, peptide drugs, represented by GLP-1 receptor agonists, have achieved breakthrough growth in the treatment of metabolic diseases, continuously driving global market expansion and indicating significant future growth potential.
Online message
WeChat Official Account
WeChat Customer Service
